Light Sciences Oncology Finishes Enrollment in Pivotal Clinical Trial

Xconomy Seattle — 

Light Sciences Oncology, a Bellevue, WA-based developer of cancer drugs, said it has completed enrollment of 200 patients with liver tumors in a clinical trial. The goal of the study is to see whether patients live longer after they get LitX. The company’s treatment is designed to use a light-emitting diode, threaded inside a tumor, to activate a drug to kill tumors within its wavelength. If the trial reaches it goal, the company plans to ask regulators in the U.S. and Europe for marketing approval in 2009.

By posting a comment, you agree to our terms and conditions.

Comments are closed.